Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $5.00 | Buy | Lake Street |
| 2/7/2024 | $5.00 | Overweight | Cantor Fitzgerald |
| 6/15/2023 | $5.00 | Equal-Weight | Morgan Stanley |
| 5/24/2023 | $10.00 | Neutral → Buy | BTIG Research |
| 11/10/2022 | Buy → Neutral | BTIG Research | |
| 8/10/2022 | Outperform → Perform | Oppenheimer | |
| 11/10/2021 | $26.00 → $20.00 | Outperform | SVB Leerink |
| 8/10/2021 | $24.00 → $25.00 | Outperform | Credit Suisse |
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound
CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the
CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services' (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based products (CTPs) under the CY 2026 Physician Fee Schedule and urges CMS to establish 2026 payment rates based on clinical value and relative cost. "We are pleased CMS is proposing a per centimeter square payment methodology based on FDA classification for skin substitutes i
Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00
Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00
Morgan Stanley initiated coverage of Organogenesis with a rating of Equal-Weight and set a new price target of $5.00
4 - Organogenesis Holdings Inc. (0001661181) (Issuer)
4 - Organogenesis Holdings Inc. (0001661181) (Issuer)
4 - Organogenesis Holdings Inc. (0001661181) (Issuer)
4 - Organogenesis Holdings Inc. (0001661181) (Issuer)
SCHEDULE 13G - Organogenesis Holdings Inc. (0001661181) (Subject)
S-8 - Organogenesis Holdings Inc. (0001661181) (Filer)
10-Q - Organogenesis Holdings Inc. (0001661181) (Filer)
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound
CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of: Net revenue from Advanced Wound Care products of $79.9 mill
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the
Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me
SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)
SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)
SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)